The Food and Drug Administration has given Lunar 510(k) clearancefor the final pieces of its automated vertebral morphometry techniquefor its Expert-XL bone densitometer. Vertebral morphometry addsinformation about bone size and shape to the bone density
The Food and Drug Administration has given Lunar 510(k) clearancefor the final pieces of its automated vertebral morphometry techniquefor its Expert-XL bone densitometer. Vertebral morphometry addsinformation about bone size and shape to the bone density dataacquired by densitometers.
Lunar's vertebral morphometry application allows clinicians tomake computerized measurements of vertebral dimensions and howthese dimensions change over time, then compare them to a referencebase of a normal population to determine whether the measurementsare abnormal. Lunar's 510(k) clearance was for use of the referencebase and adds to clearances received last year for other partsof the technology.
Automated vertebral morphometry is a major selling point of Expert-XL,according to David Weissburg, marketing manager for the Madison,WI, company. Although the technique is not in widespread clinicaluse, it has promising clinical potential and is commonly usedby pharmaceutical companies developing drugs for the treatmentof osteoporosis.
"It provides a new level of information about bone status,"Weissburg said.
Lunar is offering vertebral morphometry as an option on Expert-XLsystems, and most ship with the option. The company has been shippingthe application to overseas customers since the Expert line waslaunched in 1994, according to Weissburg.
Vertebral morphometry was an issue in a patent dispute last yearbetween Lunar and archrival Hologic of Waltham, MA. The disputewas settled with a patent cross-licensing deal between the companies(SCAN 10/11/95).
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.